Literature DB >> 26193696

Successfully treated intractable pruritus with rifampin in a case of benign recurrent intrahepatic cholestasis.

Teru Kumagi1, E Jenny Heathcote2.   

Abstract

A 56-year-old gentleman with benign recurrent intrahepatic cholestasis (BRIC) suffered from recurrent episodes of pruritus for over 40 years. The treatment prescribed, namely cholestyramine, was minimally effective. However, rifampin 150 mg b.i.d promptly and completely relieved his severe pruritus. The diagnosis of BRIC, being a rare condition, may go unrecognized. The severity of the lifelong episodes of intermittent cholestasis with pruritus in BRIC may be extremely distressing to the affected patient. Administration of rifampin during the acute episode of severe pruritus led to a marked improvement in his quality of life.

Entities:  

Keywords:  Benign recurrent intrahepatic cholestasis (BRIC); Pruritus; Rifampin

Year:  2008        PMID: 26193696     DOI: 10.1007/s12328-008-0027-y

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  23 in total

1.  Effects of long-term rifampicin administration in primary biliary cirrhosis.

Authors:  L Bachs; A Parés; M Elena; C Piera; J Rodés
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

Review 2.  Clinical pharmacokinetics of fluvastatin.

Authors:  C D Scripture; J A Pieper
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  Rifampin relieves pruritus in children with cholestatic liver disease.

Authors:  H A Cynamon; J M Andres; R P Iafrate
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

4.  Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum.

Authors:  Nancy A M van Ooteghem; Leo W J Klomp; Gerard P van Berge-Henegouwen; Roderick H J Houwen
Journal:  J Hepatol       Date:  2002-03       Impact factor: 25.083

5.  A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis.

Authors:  L N Bull; M J van Eijk; L Pawlikowska; J A DeYoung; J A Juijn; M Liao; L W Klomp; N Lomri; R Berger; B F Scharschmidt; A S Knisely; R H Houwen; N B Freimer
Journal:  Nat Genet       Date:  1998-03       Impact factor: 38.330

Review 6.  Drug interactions between oral contraceptives and antibiotics.

Authors:  B D Dickinson; R D Altman; N H Nielsen; M L Sterling
Journal:  Obstet Gynecol       Date:  2001-11       Impact factor: 7.661

7.  Use of rifampin for severe pruritus in children with chronic cholestasis.

Authors:  B Yerushalmi; R J Sokol; M R Narkewicz; D Smith; F M Karrer
Journal:  J Pediatr Gastroenterol Nutr       Date:  1999-10       Impact factor: 2.839

Review 8.  Congenital cholestatic syndromes: what happens when children grow up?

Authors:  S C Ling
Journal:  Can J Gastroenterol       Date:  2007-11       Impact factor: 3.522

9.  Treatment of pruritus of primary biliary cirrhosis with rifampin.

Authors:  A Podesta; P Lopez; R Terg; F Villamil; D Flores; R Mastai; C B Udaondo; J P Companc
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

Review 10.  Benign recurrent intrahepatic cholestasis.

Authors:  Velimir A Luketic; Mitchell L Shiffman
Journal:  Clin Liver Dis       Date:  2004-02       Impact factor: 6.126

View more
  1 in total

1.  New paradigms of USP53 disease: normal GGT cholestasis, BRIC, cholangiopathy, and responsiveness to rifampicin.

Authors:  Hamoud Alhebbi; Abdul Ali Peer-Zada; Abdulrahman A Al-Hussaini; Sara Algubaisi; Awad Albassami; Nasser AlMasri; Yasir Alrusayni; Ibrahim M Alruzug; Essa Alharby; Manar A Samman; Syed Zubair Ayoub; Sateesh Maddirevula; Roy W A Peake; Fowzan S Alkuraya; Sami Wali; Naif A M Almontashiri
Journal:  J Hum Genet       Date:  2020-08-06       Impact factor: 3.172

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.